Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM14 monotherapy and PM14 plus radiotherapy in soft tissue sarcoma and other solid tumors
2024-519893-38-00Phase 2Authorised
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ecubectedin in soft tissue sarcoma (STS), Nonhematologic neoplasms and head and neck cancer (HNC) (6 cohorts), sponsored by Spanish Group for Research on Sarcoma. Primary endpoints: Maximum tolerated dose, Progression-free survival rate at 6 months and 1 more. Planned start Dec 2024; status: authorised.
02
Drugs
ecubectedin
03
Conditions
soft tissue sarcoma (STS)Nonhematologic neoplasmshead and neck cancer (HNC)
Beyond the preview
Go deeper on 2024-519893-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519893-38-00.